Title:
TREATMENT OF CANCER WITH ANTI-OX40 ANTIBODIES AND MULTI-KINASE INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2021/098769
Kind Code:
A1
Abstract:
The present disclosure provides methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a multi-kinase inhibitor.
More Like This:
| JP2005515779 | Agrecanase molecule |
| JP3103116 | [Title of the Invention] A method for improving the stability of an antibody. |
| JP2013515697 | Influenza target |
Inventors:
JIANG BEIBEI (CN)
LIU YE (CN)
SONG XIAOMIN (CN)
LIU YE (CN)
SONG XIAOMIN (CN)
Application Number:
PCT/CN2020/130059
Publication Date:
May 27, 2021
Filing Date:
November 19, 2020
Export Citation:
Assignee:
BEIGENE LTD (KY)
JIANG BEIBEI (CN)
JIANG BEIBEI (CN)
International Classes:
A61K39/395; A61K31/4365; A61K31/444; A61P35/00; C07D495/04; C07K16/28
Foreign References:
| CN105777776A | 2016-07-20 | |||
| CN102010407A | 2011-04-13 | |||
| CN107810011A | 2018-03-16 | |||
| CN110467674A | 2019-11-19 |
Other References:
YANG， Y ET AL: "Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40", BLOOD, vol. 120, no. 23, 29 November 2012 (2012-11-29), XP055194404, DOI: 10.1182/blood-2012-02-407163
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF:
Previous Patent: METHOD AND SYSTEM FOR ASSESSING ANEURYSM RUPTURE RISK
Next Patent: DISCHARGE OUTLET FIXING ASSEMBLY AND FIXING CLAMP THEREOF
Next Patent: DISCHARGE OUTLET FIXING ASSEMBLY AND FIXING CLAMP THEREOF